HUP0103819A2 - Kristályos efavirenz, azt hatóanyagként tartalmazó gyógyszerkészítmények, valamint az efavirenz alkalmazása a HIV reverz transzkriptáz gátlására és a HIV-fertőzések kezelésére alkalmas gyógyszerkészítmény előállítására - Google Patents

Kristályos efavirenz, azt hatóanyagként tartalmazó gyógyszerkészítmények, valamint az efavirenz alkalmazása a HIV reverz transzkriptáz gátlására és a HIV-fertőzések kezelésére alkalmas gyógyszerkészítmény előállítására

Info

Publication number
HUP0103819A2
HUP0103819A2 HU0103819A HUP0103819A HUP0103819A2 HU P0103819 A2 HUP0103819 A2 HU P0103819A2 HU 0103819 A HU0103819 A HU 0103819A HU P0103819 A HUP0103819 A HU P0103819A HU P0103819 A2 HUP0103819 A2 HU P0103819A2
Authority
HU
Hungary
Prior art keywords
efavirenz
inhibitions
active ingredient
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0103819A
Other languages
English (en)
Inventor
Michael B. Maurin
James R. Moore
Shelley R. Rabel
Lilian A. Radesca
Original Assignee
Du Pont Pharmaceuticals Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22214647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0103819(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Du Pont Pharmaceuticals Co. filed Critical Du Pont Pharmaceuticals Co.
Publication of HUP0103819A2 publication Critical patent/HUP0103819A2/hu
Publication of HUP0103819A3 publication Critical patent/HUP0103819A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HU0103819A 1998-06-11 1999-06-10 Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection HUP0103819A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8898198P 1998-06-11 1998-06-11
PCT/US1999/013199 WO1999064405A1 (en) 1998-06-11 1999-06-10 Crystalline efavirenz

Publications (2)

Publication Number Publication Date
HUP0103819A2 true HUP0103819A2 (hu) 2002-02-28
HUP0103819A3 HUP0103819A3 (en) 2003-05-28

Family

ID=22214647

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103819A HUP0103819A3 (en) 1998-06-11 1999-06-10 Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection

Country Status (21)

Country Link
EP (1) EP1086087A1 (hu)
JP (1) JP2002517487A (hu)
CN (1) CN1307568A (hu)
AR (3) AR018670A1 (hu)
AU (1) AU758114C (hu)
BR (1) BR9911523A (hu)
CA (1) CA2333550A1 (hu)
EE (1) EE05547B1 (hu)
HR (1) HRP990182A2 (hu)
HU (1) HUP0103819A3 (hu)
IL (1) IL139793A (hu)
MY (1) MY126450A (hu)
NO (1) NO20006255L (hu)
NZ (1) NZ507713A (hu)
PL (1) PL198504B1 (hu)
SG (3) SG134977A1 (hu)
SK (1) SK18182000A3 (hu)
TW (1) TWI235152B (hu)
UA (1) UA74324C2 (hu)
WO (1) WO1999064405A1 (hu)
ZA (1) ZA200006173B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
PE20060587A1 (es) * 2004-09-02 2006-07-09 Bristol Myers Squibb Co Sintesis de (s)-6-cloro-4-ciclopropiletinil-4-trifluorometil-1,4-dihidro-2h-3,1-benzoxazin-2-ona
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009011567A1 (en) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Crystalline forms of efavirenz
MX2010008535A (es) 2008-02-04 2010-08-30 Pfizer Ltd Forma polimorfa de un derivado de [1,2,4] triazolo [4,3-a] piridina para tratamiento de enfermedades inflamatorias.
US8383811B2 (en) 2008-12-22 2013-02-26 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN102924398B (zh) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
AU2013375157B2 (en) * 2013-01-23 2018-07-12 Alienor Farma Increased dosage of Efavirenz for the treatment of cancer
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
CN105001101B (zh) * 2015-05-28 2017-11-28 乐平市瑞盛制药有限公司 一种4‑氯‑2‑三氟乙酰基苯胺水合物盐酸盐的合成方法
CN108947855B (zh) * 2018-08-10 2021-10-22 江苏沙星化工有限公司 一种依非韦伦关键中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
AU3736197A (en) * 1996-07-26 1998-02-20 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcripta se inhibitors
WO1998014436A1 (en) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same
CN1073991C (zh) * 1997-02-05 2001-10-31 麦克公司 使用抗溶剂的逆转录酶抑制剂结晶工艺

Also Published As

Publication number Publication date
AU758114B2 (en) 2003-03-13
SG111981A1 (en) 2005-06-29
ZA200006173B (en) 2001-10-31
WO1999064405A1 (en) 1999-12-16
BR9911523A (pt) 2001-09-18
PL198504B1 (pl) 2008-06-30
MY126450A (en) 2006-10-31
UA74324C2 (uk) 2005-12-15
AR077469A2 (es) 2011-08-31
JP2002517487A (ja) 2002-06-18
HUP0103819A3 (en) 2003-05-28
AR018670A1 (es) 2001-11-28
IL139793A (en) 2006-10-31
EP1086087A1 (en) 2001-03-28
EE05547B1 (et) 2012-06-15
IL139793A0 (en) 2002-02-10
NO20006255L (no) 2001-02-12
CN1307568A (zh) 2001-08-08
EE200000743A (et) 2002-10-15
NO20006255D0 (no) 2000-12-08
HRP990182A2 (en) 2000-02-29
AU4436499A (en) 1999-12-30
PL345221A1 (en) 2001-12-03
SG111980A1 (en) 2005-06-29
AU758114C (en) 2003-10-30
CA2333550A1 (en) 1999-12-16
AR077407A2 (es) 2011-08-24
NZ507713A (en) 2003-08-29
SG134977A1 (en) 2007-09-28
SK18182000A3 (sk) 2001-08-06
TWI235152B (en) 2005-07-01

Similar Documents

Publication Publication Date Title
HUP0103819A3 (en) Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection
IL143512A (en) Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus
EE200000532A (et) Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ningkombineeritud preparaat kasutamiseks HIV nakkusera
DE69931159D1 (de) Antimikrobielle zusammensetzungen enthaltend taurolidin, zitronensäure und natriumzitrat
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
EE200200202A (et) Uudsed tritsüklilised ühendid, nende saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud HIV-nakkuse raviks, ning neid sisaldav farmatseutiline kompositsioon
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
BR9811298A (pt) Uso de um composto de vanádio fisiologicamente aceitável
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
ZA991029B (en) Composition and methods for treatment of hiv infections.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
AU7547100A (en) Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
AU1556000A (en) Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
PL345309A1 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
WO2002055520A3 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
HUP0103623A3 (en) Bispiperidines as antithrombotic agents, their process for preparation and medicament containing them as active ingredient

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished